Novel therapeutic targets along the Th17 pathway.
The recent discovery of IL-17-producing CD4(+) Th subset significantly revised the Th1/Th2 dichotomy model proposed by Mosmann and Coffman almost two decades ago. Th17 cells are involved in the pathogenesis of many human autoimmune diseases. Th17 cells, their developmental pathways and their effector functions, therefore, provide novel therapeutic targets.
Ouyang
Wenjun
W
Department of Immunology, Genentech, South San Francisco, CA 94080, USA. ouyang@gene.com
Filvaroff
Ellen
E
Hu
Yan
Y
Grogan
Jane
J
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000276:immunology*; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D057132:Nuclear Receptor Subfamily 1, Group F, Member 3; D016376:Oligonucleotides, Antisense / Q000276:immunology / Q000627:therapeutic use; D018336:Receptors, Aryl Hydrocarbon / Q000276:immunology / Q000378:metabolism; D018168:Receptors, Retinoic Acid / Q000276:immunology / Q000378:metabolism; D011988:Receptors, Thyroid Hormone / Q000276:immunology / Q000378:metabolism; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology* / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors / Q000276:immunology*
D000911:Antibodies, Monoclonal; D016207:Cytokines; D020381:Interleukin-17; D057132:Nuclear Receptor Subfamily 1, Group F, Member 3; D016376:Oligonucleotides, Antisense; C539900:RORC protein, human; D018336:Receptors, Aryl Hydrocarbon; D018168:Receptors, Retinoic Acid; D011988:Receptors, Thyroid Hormone; D016212:Transforming Growth Factor beta